Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study

被引:1
作者
Adams, J. L. [1 ,2 ]
Murray, M. [3 ,4 ]
Patel, N. [5 ,6 ]
Sawkin, M. T. [7 ]
Boardman, R. C. [1 ]
Pham, C. [1 ]
Kaur, H. [1 ]
Patel, D. [1 ]
Yager, J. L. [8 ]
Pontiggia, L. [9 ]
Baxter, J. [2 ,10 ]
机构
[1] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA
[2] Cooper Univ Hosp, Div Infect Dis, Camden, NJ USA
[3] Midwestern Univ, Chicago Coll Pharm, Downers Grove, IL 60515 USA
[4] Northwestern Mem Hosp, Chicago, IL 60611 USA
[5] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA
[6] Albany Stratton VA Med Ctr, Albany, NY USA
[7] KC CARE Hlth Ctr, Kansas City, MO USA
[8] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[9] Univ Sci, Misher Coll Arts & Sci, Philadelphia, PA USA
[10] Rowan Univ, Cooper Med Sch, Camden, NJ USA
关键词
antiretroviral therapy; baseline viral load; integrase inhibitors; protease inhibitors; reverse transcriptase inhibitors; viral suppression; DOUBLE-BLIND; TENOFOVIR ALAFENAMIDE; INITIAL TREATMENT; THERAPY; PHASE-3; EMTRICITABINE; ADULTS; IMPACT; DOLUTEGRAVIR; BICTEGRAVIR;
D O I
10.1111/hiv.12959
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives We aimed to compare the effectiveness of antiretroviral therapy (ART) classes for achieving HIV RNA suppression to < 50 HIV-1 RNA copies/mL within 6 months of initiation with high viral loads (VLs). Secondary objectives were to compare viral suppression (VS) at 12 weeks and 12 months, partial HIV RNA suppression to < 200 copies/mL, time to VS, time to rebound, and change in CD4 cell count. Methods This was a multicentre, retrospective, observational study. Adult patients were included if they initiated ART between January 2005 and December 2016 with a VL >= 100 000 copies/mL. Results There were 220 patients included in the study. The median VL was 252 919 [interquartile range (IQR) 149 472-500 000] copies/mL. Nonnucleoside reverse transcriptase inhibitor (NNRTI) recipients were more likely to achieve VS by 6 months compared to those initiating ART containing protease inhibitors (PIs) [75.4%vs. 44.1%, respectively; odds ratio (OR) 3.34; 95% confidence interval (CI) 1.62-6.90] or integrase strand transfer inhibitors (INSTIs) (75.4%vs. 55.8%, respectively; OR 2.40; 95% CI 1.03-5.58). VS at 12 weeks was more frequent with INSTI-containing regimens than with PIs (28.9%vs. 9.0%, respectively; OR 4.10; 95% CI 1.69-9.92). VS at 12 months did not significantly differ between treatment regimens. Median time to complete VS for INSTI, PI and NNRTI recipients was 22.3 (95% CI 13.4-33), 30.1 (95% CI 25-36) and 19.9 (95% CI 16-22.3) weeks, respectively. There were no significant differences in time to viral rebound or change in CD4 cell counts. Conclusions Patients with high VLs initiated on NNRTIs were more likely to achieve VS by 6 months on ART compared to INSTI and PI recipients.
引用
收藏
页码:28 / 36
页数:9
相关论文
共 21 条
[1]  
[Anonymous], Guidelines for the use of antiretroviral agents in adults and adolescents with HIV
[2]   British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 [J].
Churchill, Duncan ;
Waters, Laura ;
Ahmed, Nadia ;
Angus, Brian ;
Boffito, Marta ;
Bower, Mark ;
Dunn, David ;
Edwards, Simon ;
Emerson, Carol ;
Fidler, Sarah ;
Fisher, Martin ;
Horne, Rob ;
Khoo, Saye ;
Leen, Clifford ;
Mackie, Nicola ;
Marshall, Neal ;
Monteiro, Fernando ;
Nelson, Mark ;
Orkin, Chloe ;
Palfreeman, Adrian ;
Pett, Sarah ;
Phillips, Andrew ;
Post, Frank ;
Pozniak, Anton ;
Reeves, Iain ;
Sabin, Caroline ;
Trevelion, Roy ;
Walsh, John ;
Wilkins, Ed ;
Williams, Ian ;
Winston, Alan .
HIV MEDICINE, 2016, 17 :S2-S104
[3]   Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial [J].
Cohen, Calvin J. ;
Andrade-Villanueva, Jaime ;
Clotet, Bonaventura ;
Fourie, Jan ;
Johnson, Margaret A. ;
Ruxrungtham, Kiat ;
Wu, Hao ;
Zorrilla, Carmen ;
Crauwels, Herta ;
Rimsky, Laurence T. ;
Vanveggel, Simon ;
Boven, Katia .
LANCET, 2011, 378 (9787) :229-237
[4]  
Gallant J, 2017, LANCET, V390, P2063, DOI [10.1016/S0140-6736(17)32299-7, 10.1016/s0140-6736(17)32299-7]
[5]   Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load [J].
Gerardus, Stephan ;
Guido, Papendorp ;
van den Berk, E. .
AIDS, 2009, 23 (06) :739-739
[6]  
Llibre JM, 2015, AIDS REV, V17, P56
[7]   Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection [J].
Lundgren, Jens D. ;
Babiker, Abdel G. ;
Gordin, Fred ;
Emery, Sean ;
Sharma, Shweta ;
Avihingsanon, An-Chalee ;
Cooper, David A. ;
Faetkenheuer, Gerd ;
Llibre, Josep M. ;
Moli-Na, Jean-Michel ;
Munderi, Paula ;
Schechter, Mauro ;
Wood, Robin ;
Klingman, Karin L. ;
Collins, Simon ;
Lane, H. Clifford ;
Phillips, Andrew N. ;
Neaton, James D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (09) :795-807
[8]   Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals [J].
Markowitz, Martin ;
Morales-Ramirez, Javier O. ;
Nguyen, Bach-Yen ;
Kovacs, Colin M. ;
Steigbigel, Roy T. ;
Cooper, David A. ;
Liporace, Ralph ;
Schwartz, Robert ;
Isaacs, Robin ;
Gilde, Lucinda R. ;
Penning, Larissa ;
Zhao, Jing ;
Teppler, Hedy .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) :509-515
[9]  
Mills AM, 2019, IAS C HIV SCI JUL 21
[10]   Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial [J].
Molina, Jean-Michel ;
Squires, Kathleen ;
Sax, Paul E. ;
Cahn, Pedro ;
Lombaard, Johan ;
DeJesus, Edwin ;
Lai, Ming-Tain ;
Xu, Xia ;
Rodgers, Anthony ;
Lupinacci, Lisa ;
Kumar, Sushma ;
Sklar, Peter ;
Bach-Yen Nguyen ;
Hanna, George J. ;
Hwang, Carey .
LANCET HIV, 2018, 5 (05) :E211-E220